Parmiani G, Fossati G, Taramelli D, Anichini A, Balsari A, Gambacorti-Passerini C, Sciorelli G, Cascinelli N
Cancer Metastasis Rev. 1985;4(1):7-26. doi: 10.1007/BF00047734.
Evidence for heterogeneity of several biological features of human malignant melanoma (Me) like morphology, cytogenetics, oncogenes activation, antigenic expression, metastatizing capacity and procoagulant activity are briefly reviewed in an attempt to distinguish findings related to primary vs. metastatic lesions. In our own studies monoclonal antibodies were used to study expression of MHC class I, class II products and of Me-associated antigens (MAA) on primary and metastatic Me cells. High expression of class I antigens was found in a high percentage of both primary and metastatic tumors, whereas DR and MAA showed a significant variation (from 3 to 90% of cells) in expression both in primary and in metastatic Me. When autologous cell-mediated immune responses were evaluated, it was found that Me cells from primary tumors but not those from lymph node metastases were able to stimulate autologous lymphocytes to proliferate and become cytotoxic for autologous Me. Clonal analysis of cytotoxic lymphocytes was then carried out in order to see whether the lack of lymphocytes reactivity to metastatic cells was due to the absence or to a low frequency of cytotoxic cells in the unstimulated PBL. CTL clones cytotoxic for autologous Me (Auto-Me) cells were indeed isolated. Three classes of CTL clones were identified: 1) one which is cytotoxic for Auto-Me; 2) a second one which lyse Auto-Me and allogeneic Me; and 3) a third one which is cytotoxic for Auto-Me and allogeneic normal and neoplastic cells. Metastatic Me cells, however, had the ability to suppress the stimulation of autologous PBL by alloantigens or IL-2. This effect was dose-dependent and was not due to absorption of IL-2 by Me cells. Since it has been reported that Me cells express class II MHC antigens, we investigated whether there was any correlation between autologous immune responses and DR expression on Me cells. Autologous lymphocytes stimulation was found to occur only with DR+ Me cells from primary lesions, whereas metastatic cells, either DR+ or DR-, did not stimulate autologous PBL. Moreover, the suppressive effect of metastatic Me cells was associated with their expression of DR antigens. The modulation of DR antigens on Me cells by Interferon-gamma correlated positively with their suppressive capacity. Thus, it appears that primary Me can behave differently from the metastatic one in their interactions with the immune system of autologous host. These findings suggest that DR antigens on Me cells may have an important role in the regulation of autologous immune responses.
本文简要综述了人类恶性黑色素瘤(Me)在形态学、细胞遗传学、癌基因激活、抗原表达、转移能力和促凝活性等几种生物学特征方面的异质性证据,旨在区分与原发性和转移性病变相关的研究结果。在我们自己的研究中,使用单克隆抗体来研究MHC I类、II类产物以及Me相关抗原(MAA)在原发性和转移性Me细胞上的表达。在高比例的原发性和转移性肿瘤中都发现了I类抗原的高表达,而DR和MAA在原发性和转移性Me中的表达均有显著差异(从3%到90%的细胞)。当评估自体细胞介导的免疫反应时,发现原发性肿瘤的Me细胞能够刺激自体淋巴细胞增殖并对自体Me产生细胞毒性,而淋巴结转移灶的Me细胞则不能。随后对细胞毒性淋巴细胞进行克隆分析,以确定淋巴细胞对转移细胞缺乏反应性是否是由于未刺激的外周血淋巴细胞(PBL)中细胞毒性细胞的缺失或频率较低。确实分离出了对自体Me(Auto-Me)细胞具有细胞毒性的CTL克隆。鉴定出了三类CTL克隆:1)一类对Auto-Me具有细胞毒性;2)另一类能裂解Auto-Me和同种异体Me;3)第三类对Auto-Me以及同种异体正常和肿瘤细胞具有细胞毒性。然而,转移性Me细胞能够抑制同种异体抗原或IL-2对自体PBL的刺激。这种效应是剂量依赖性的,并非由于Me细胞吸收了IL-2。由于已有报道称Me细胞表达II类MHC抗原,我们研究了自体免疫反应与Me细胞上DR表达之间是否存在任何相关性。发现仅原发性病变的DR+Me细胞能刺激自体淋巴细胞,而转移性细胞,无论DR+还是DR-,均不能刺激自体PBL。此外,转移性Me细胞的抑制作用与其DR抗原的表达相关。干扰素-γ对Me细胞上DR抗原的调节与其抑制能力呈正相关。因此,原发性Me与转移性Me在与自体宿主免疫系统的相互作用中表现可能不同。这些发现表明Me细胞上的DR抗原可能在自体免疫反应的调节中起重要作用。